Presmin Combo Filmuhúðuð tafla 50/12,5 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

presmin combo filmuhúðuð tafla 50/12,5 mg

alvogen ehf. - losartanum kalíum; hydrochlorothiazidum inn - filmuhúðuð tafla - 50/12,5 mg

Presmin Combo Filmuhúðuð tafla 100/25 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

presmin combo filmuhúðuð tafla 100/25 mg

alvogen ehf. - losartanum kalíum; hydrochlorothiazidum inn - filmuhúðuð tafla - 100/25 mg

Cozaar Comp Forte Filmuhúðuð tafla 100/25 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

cozaar comp forte filmuhúðuð tafla 100/25 mg

n.v. organon* - losartanum kalíum; hydrochlorothiazidum inn - filmuhúðuð tafla - 100/25 mg

Cozaar Comp Filmuhúðuð tafla 50+12,5 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

cozaar comp filmuhúðuð tafla 50+12,5 mg

n.v. organon* - losartanum kalíum; hydrochlorothiazidum inn - filmuhúðuð tafla - 50+12,5 mg

Rozlytrek Evropska unija - islandščina - EMA (European Medicines Agency)

rozlytrek

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - Æxlishemjandi lyf - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Evkeeza Evropska unija - islandščina - EMA (European Medicines Agency)

evkeeza

ultragenyx germany gmbh - evinacumab - kólesterólhækkun - lipid breytandi lyf - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).